Navigation Links
Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
Date:6/8/2009

will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
2. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
3. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
4. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
5. Micromet Key Events for 2009
6. Micromet Expands Committed Equity Financing Facility to $75 Million
7. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
8. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
9. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat ... fiscal 2015 first quarter ended June 30, 2014.  ...  PC Neuromodulation System grew 19% to $4.1 million, ... quarter of the prior year.  Total revenue for ...
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... July 14 Samsung Medical Center and the world,s leading bio-pharmaceutical company ... research partnership to jointly analyze tumors from Korean patients to generate gene expression ... patients with liver cancer. , , ... http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) , , , ...
... , SANTA ROSA, Calif. , July 14 ... Santa Rosa, California , today received a notice of ... company which was started in 2006 has thirteen additional patent ... the world for related spinal therapies and devices. The lead ...
Cached Medicine Technology:Pfizer and SMC Collaborate on Liver Cancer 2Pfizer and SMC Collaborate on Liver Cancer 3Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices 2
(Date:7/25/2014)... Newyorktermlifeinsurance.org has released a new ... and traditional policies. , The newly released blog ... no medical exam life insurance plans and traditional policies. ... insurance plans to provide a simple guide for purchasing ... can now be purchased online. Although traditional plans do ...
(Date:7/25/2014)... In today’s technological era, every organization ... devices. This benefits the organization in various ways. But ... which can destroy the confidential information and processes of ... Compliance (EGRC) manage and protect the enterprise from various ... loss in dollars to the comp may. The equipment's ...
(Date:7/25/2014)... July 25, 2014 The European liquid ... in Europe with analysis and forecast of revenue. The ... $ 1007.2 million in 2013, and is estimated to ... CAGR of 9.4 %, from 2013 to 2018. , ... reagents market, to get an idea of the in-depth ...
(Date:7/25/2014)... -- Although cervical cancers are declining in the United ... (HPV) are increasing, a new study indicates. HPV-related ... tongue and tonsils have increased over the past 35 ... the Canadian researchers report. "The increases in the ... of anal cancer among younger women are disturbing, because ...
(Date:7/25/2014)... July 25, 2014 Innerspire, LLC ( ... the company as a Creative Enrollment Specialist. In this ... building skills as well as his accomplished design skills ... business clients, and to service the creative marketing ... Greg will work with small business owners and individuals ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4
... PAUL, Minn., Jan. 29 U.S. President Barack ... on human embryonic stem cells (hESC) research and is ... the issue. On Aug. 9, 2001, the Bush administration ... those hESC lines derived before that date. Jonathan ...
... have complications, without ill effects, study finds , , THURSDAY, Jan. ... to babies still in the womb can reduce their post-birth ... growth the way multiple courses can, new research shows. , ... those given a second dose of steroids in utero had ...
... PRO Educational Initiative are AnnouncedPITTSBURGH, Jan. 29 ... electronic patient reported outcomes (ePRO) solutions and ... opened registration for ePROficiency(TM) 2009 -- its ... research professionals can visit http://www.invivodata.com/epro2009 ...
... American businesses take belt-,tightening to new levels to ... a new service to help organizations address one ... EquivaMeds ( www.EquivaMeds.com ) helps self-insured ... helps members analyze their,current medications, identify lower cost ...
... interventions developed by UCSF researchers have been selected ... and Prevention,s 2008 Compendium of Evidence-based HIV Prevention ... Video Doctor and the Healthy Living Projectcomprise two ... 57 rigorously evaluated highly effective HIV prevention programs ...
... BTA stat(R) Test Detects Bladder Tumor Associated Antigen in UrineCORTLANDT ... announce the direct availability of the BTA stat (R) ... (R) test is a point of care technology for the ... antibodies to detect the presence of bladder tumor associated antigen ...
Cached Medicine News:Health News:University of Minnesota's Internationally Recognized Stem Cell Experts Available for Interviews on What Lifting the Federal Funding Restrictions Will Mean to Stem Cell Research and to Patients Who Stand to Benefit 2Health News:Additional Steroid Dose May Help Preemies 2Health News:Additional Steroid Dose May Help Preemies 3Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 2Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 3Health News:CDC recognizes UCSF's research as critical to HIV prevention 2Health News:CDC recognizes UCSF's research as critical to HIV prevention 3Health News:Polymedco Introduces Point of Care Test for Recurrent Bladder Cancer Detection 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: